Company news
Painchek Ltd (ASX:PCK) news
Painchek Ltd news releases on 6ix. Latest, Aug 28, 2026: Appendix 4E and Financial Report
Press releases & updates
Appendix 4E and Financial Report
August 28, 2026
PainChek receives $1.123 million R&D tax incentive refund
July 21, 2026
US MedTech leader Karen Holzberger appointed CEO
July 19, 2026
CEO Transition
July 6, 2026
PainChek secures A$5.5m note to fund US expansion
May 21, 2026
Landmark Sabra North America deployment targeting 20k beds
April 13, 2026
PainChek reports material sales momentum in UK
March 25, 2026
Half Yearly Report and Accounts
February 27, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
PainChek Business Update
January 29, 2026
PainChek gains access to RTM reimbursement in USA
January 28, 2026
AGM Presentation
November 25, 2025
Investor Presentation
October 30, 2025
Notice of Annual General Meeting/Proxy Form
October 24, 2025
Key hire to drive Infant App in $15Bn addressable market
October 16, 2025
Response to ASX Aware Letter
October 16, 2025
PainChek Secures First US Customer Following FDA Clearance
October 12, 2025
PainChek FDA Cleared to Commence Sales in US$100M US Market
October 8, 2025
Trading Halt
October 6, 2025
Compelling Clinical and Economic Results in Scottish Pilot
September 16, 2025
Preliminary Final Report
August 28, 2025
Strongly Supported A$7.5m Placement to Drive Int. Growth
July 28, 2025
Final US FDA De Novo Clearance Submission Completed
July 20, 2025
PainChek Reports Strong Quarterly Sales Growth
July 2, 2025
PainChek has productive final FDA De Novo clearance meeting
June 4, 2025
PainChek partners with Eldermark to expand US market reach
May 26, 2025
R&D Tax Refund, FDA Review of Adult App & Infant App Launch
April 15, 2025
PainChek completes Entitlement Offer raising AUD $5.1 m
December 16, 2024
PainChek Implementations, Market and International Expansion
December 10, 2024
Prospectus
November 24, 2024
Underwritten Entitlement Offer to raise AUD $5.1million
November 24, 2024
PCK submits application for Adult App FDA De Novo clearance
November 19, 2024
PCK expands market reach with BESTMED reseller agreement
November 12, 2024
Positive study results pave way for PainChek FDA submission
October 28, 2024
PainChek Adult app FDA De Novo submission update
October 1, 2024
PainChek receives European patent for pain assessment tech
May 27, 2024
PainChek receives $1,210,000 R&D Tax Incentive Refund
April 22, 2024
PainChek UK partnership with Nourish Care
March 13, 2024
PainChek completes A$5m capital raise
March 13, 2024
PainChek Share Purchase Plan oversubscribed
March 6, 2024
Underwritten Share Purchase Plan to raise AUD $2.5 million
February 13, 2024
Notice of Acceptance for European Patent
November 20, 2023
Quarterly Update and Appendix 4C
October 30, 2023
Response to ASX Price Query
October 9, 2023
PainChek A$3.55m Placement
September 14, 2023
US nursing home study to pave way for FDA De Novo clearance
August 24, 2023
PainChek receives $1.049m R&D Tax Incentive Refund
July 24, 2023
Ethos Laboratories Distribution Agreement
June 15, 2023
AGM CEO Presentation
November 22, 2022
Response to ASX Query
September 30, 2022